Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have received a consensus recommendation of “Hold” from the twelve analysts that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $49.50.
GMAB has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, July 18th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Truist Financial increased their price target on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Finally, BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th.
Read Our Latest Stock Analysis on Genmab A/S
Institutional Trading of Genmab A/S
Genmab A/S Trading Up 0.4 %
GMAB opened at $28.48 on Tuesday. Genmab A/S has a 12 month low of $24.53 and a 12 month high of $41.58. The stock has a 50-day moving average of $27.01 and a 200 day moving average of $28.35. The firm has a market cap of $18.84 billion, a P/E ratio of 23.73, a P/E/G ratio of 1.01 and a beta of 0.97.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The firm had revenue of $603.30 million for the quarter, compared to the consensus estimate of $594.23 million. On average, research analysts forecast that Genmab A/S will post 1.13 earnings per share for the current fiscal year.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- 3 Warren Buffett Stocks to Buy Now
- Survey: Top 175 Fittest Retirement Locations in America
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- The How And Why of Investing in Oil Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.